Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 89.00% is in line with its 5-year average of 88.71%, near the high end of its 5-year range (50.00%–95.83%).
0.01% below its 12-month average of 89.00%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 87.47%.
GROSS MARGIN
89.00%
GROSS MARGIN AVG TTM
89.00%
GROSS MARGIN AVG 3Y
88.74%
GROSS MARGIN AVG 5Y
88.71%
GROSS MARGIN AVG 10Y
46.47%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.01%
CURRENT VS 3Y AVG
+0.29%
CURRENT VS 5Y AVG
+0.33%
CURRENT VS 10Y AVG
+91.50%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.38%
median of 786 covered companies
CURRENT VS SECTOR MEDIAN
+120.41%
vs the sector median at left
Rhythm Pharmaceuticals, Inc.
Market Cap
$6.23B
Gross Margin
89.00%
TTM Avg
89.00%
3Y Avg
88.74%
5Y Avg
88.71%
Market Cap
$6.49B
Gross Margin
39.32%
TTM Avg
37.08%
3Y Avg
36.51%
5Y Avg
35.71%
Market Cap
$6.50B
Gross Margin
60.14%
TTM Avg
62.77%
3Y Avg
60.62%
5Y Avg
54.58%
Market Cap
$5.94B
Gross Margin
98.58%
TTM Avg
95.46%
3Y Avg
84.33%
5Y Avg
82.16%
Market Cap
$6.58B
Gross Margin
73.84%
TTM Avg
76.65%
3Y Avg
78.21%
5Y Avg
76.94%
Market Cap
$5.92B
Gross Margin
97.23%
TTM Avg
60.83%
3Y Avg
-170.72%
5Y Avg
-113.81%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rhythm Pharmaceuticals, Inc. (RYTM) | $6.23B | 89.00% | 89.00% | 88.74% | 88.71% |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.49B | 39.32% | 37.08% | 36.51% | 35.71% |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.50B | 60.14% | 62.77% | 60.62% | 54.58% |
| GRAIL Inc. (GRAL)vs › | $6.00B | -42.52% | -52.32% | -104.24% | -183.56% |
| Immunovant, Inc. (IMVT)vs › | $6.55B | 0.00% | 0.00% | 0.00% | 0.00% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.94B | 98.58% | 95.46% | 84.33% | 82.16% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.58B | 73.84% | 76.65% | 78.21% | 76.94% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.92B | 97.23% | 60.83% | -170.72% | -113.81% |
| Chemed Corporation (CHE)vs › | $6.66B | 30.44% | 32.55% | 34.06% | 34.32% |
| Kodiak Sciences Inc. (KOD)vs › | $5.82B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
89.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 87.47% |
| 2026-03-31 | 88.09% |
| 2025-12-31 | 91.61% |
| 2025-09-30 | 89.28% |
| 2025-06-30 | 88.57% |
| 2025-03-31 | 88.85% |
| 2024-12-31 | 90.95% |
| 2024-09-30 | 88.49% |
| 2024-06-30 | 89.87% |
| 2024-03-31 | 89.19% |
| 2023-12-31 | 86.66% |
| 2023-09-30 | 89.28% |
| 2023-06-30 | 88.37% |
| 2023-03-31 | 87.61% |
| 2022-12-31 | 88.30% |
| 2022-09-30 | 88.40% |
| 2022-06-30 | 95.83% |
| 2022-03-31 | 84.65% |
| 2021-12-31 | 87.01% |
| 2021-09-30 | 78.40% |
| 2021-06-30 | 50.00% |
| 2021-03-31 | 88.57% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
| 2013-12-31 | 0.00% |
